FDA Approves Genentech’s Alecensa as First-line Therapy for ALK-positive, Advanced NSCLC
Lung Cancer, News
The U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib), by Genentech, as a front-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Results from ... Read more